Malaysia: +603 2779 0098
Belapectin, a galectin-3 (Gal-3) inhibitor, is in development for the prevention of esophageal varices in patients with NASH cirrhosis. Patients with cirrhosis need a therapeutic breakthrough as, currently, their only hope is a liver transplant.
Pol Boudes focuses here on to a phase 2 study looking at the perfomance of belapectin.
Only products with same currency can be added to the basket. Clear the basket or finish the order, before adding products with another currency to the basket.
